Evidence map›Paper›PMID 37520553›Full record

ArticleFrontiers in immunology2023

On the feasibility of using TCR sequencing to follow a vaccination response - lessons learned.

Peter C de Greef, Josien Lanfermeijer, Marion Hendriks, Alper Cevirgel, Martijn Vos, José A M Borghans, Debbie van Baarle, Rob J de Boer

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Peter C de GreefTheoretical Biology and Bioinformatics, Utrecht University, Utrecht, Netherlands.
Josien LanfermeijerCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
Marion HendriksCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
Alper CevirgelCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
Martijn VosCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
José A M BorghansCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands.
Debbie van BaarleCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
Rob J de BoerTheoretical Biology and Bioinformatics, Utrecht University, Utrecht, Netherlands.
National Institute for Public Health and the Environment · NLUniversity Medical Center Utrecht · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cells recognize pathogens by their highly specific T-cell receptor (TCR), which can bind small fragments of an antigen presented on the Major Histocompatibility Complex (MHC). Antigens that are provided through vaccination cause specific T cells to respond by expanding and forming specific memory to combat a future infection. Quantification of this T-cell response could improve vaccine monitoring or identify individuals with a reduced ability to respond to a vaccination. In this proof-of-concept study we use longitudinal sequencing of the TCRβ repertoire to quantify the response in the CD4+ memory T-cell pool upon pneumococcal conjugate vaccination. This comes with several challenges owing to the enormous size and diversity of the T-cell pool, the limited frequency of vaccine-specific TCRs in the total repertoire, and the variation in sample size and quality. We defined quantitative requirements to classify T-cell expansions and identified critical parameters that aid in reliable analysis of the data. In the context of pneumococcal conjugate vaccination, we were able to detect robust T-cell expansions in a minority of the donors, which suggests that the T-cell response against the conjugate in the pneumococcal vaccine is small and/or very broad. These results indicate that there is still a long way to go before TCR sequencing can be reliably used as a personal biomarker for vaccine-induced protection. Nevertheless, this study highlights the importance of having multiple samples containing sufficient T-cell numbers, which will support future studies that characterize T-cell responses using longitudinal TCR sequencing.

Indexed as

Receptors, Antigen, T-CellVaccinationCD4-Positive T-LymphocytesFeasibility StudiesHumansReceptors, Antigen, T-Cellhigh-throughput sequencingimmune responsepneumococcal 13-valent polysaccharide vaccineTCR - T cell receptorvaccination

Identifiers

PMID37520553
PMCPMC10374308
OpenAlexW4384155878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.